Daiichi commits up to $650M to Charleston Labs for nausea drugs
Daiichi Sankyo Co. Ltd. is investing up to $650 million in a Charleston Laboratories Inc. subsidiary to back development and U.S. commercialization of its hydrocodone combination drug portfolio, including CL-108, a late-stage therapy providing the pain relief of hydrocodone without the common nausea and vomiting associated with the widely prescribed opioid.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter